Advances in Cutaneous Squamous Cell Carcinoma Management

Area of Science:

• Dermatology
• Oncology

Background:

• Cutaneous squamous cell carcinoma (cSCC) prevalence is rising due to increased lifespans and better survival rates for at-risk conditions.
• cSCC mortality is significant, exceeding melanoma in the US and nearing it globally.

Purpose of the Study:

• To review recent advancements in cSCC management.
• To highlight new treatment options, risk stratification, treatment optimization, and prevention strategies for cSCC.

Main Methods:

• Review of current literature and clinical trials in cSCC management.
• Focus on novel therapeutic agents and evolving clinical practices.

Main Results:

• Immune checkpoint inhibitors (ICIs) targeting PD-1/PD-L1 represent a breakthrough for advanced cSCC.
• ICIs offer reduced toxicity, more durable responses, and improved survival compared to traditional chemotherapy.
• Ongoing clinical trials are exploring novel treatments with potential future impact.

Conclusions:

• Significant progress has been made in cSCC management, particularly with the introduction of ICIs.
• Future research and clinical trials promise further improvements in cSCC treatment and prevention.